Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent

Leukemia

Volumn 26, Issue 8, 2012, Pages 1771-1778

  Benezra, M ^a   Phillips, E ^a   Tilki, D ^b   Ding, B S ^b   Butler, J ^b   Dobrenkov, K ^a,e   Siim, B ^c   Chaplin, D ^c   Rafii, S ^b   Rabbany, S ^b,d   Bradbury, M S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c OXiGENE Inc   (United States)

^d HOFSTRA UNIVERSITY   (United States)

^e LINCOLN MEDICAL AND MENTAL HEALTH CENTER   (United States)

Author keywords

GFP; HL 60; luciferase; OXi4503

Indexed keywords

COMBRETASTATIN A1 DIPHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; CYTARABINE; GREEN FLUORESCENT PROTEIN; LUCIFERASE; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER SURVIVAL; CELL HOMING; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL; MONITORING; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CELL TRACKING; DIPHOSPHATES; GENES, REPORTER; HL-60 CELLS; HUMANS; LEUKEMIA; LUMINESCENT MEASUREMENTS; MICE; STILBENES; TRANSDUCTION, GENETIC; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864880220     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.48     Document Type: Article

References (38)

1. Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 2007; 6: 149-165.
2. Jeha S. New therapeutic strategies in acute lymphoblastic leukemia. Semin Hematol 2009; 46: 76-88.
3. Petit I, Karajannis MA, Vincent L, Young L, Butler J, Hooper AT et al. The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood 2008; 111: 1951-1961.
4. Ninomiya M, Abe A, Katsumi A, Xu J, Ito M, Arai F et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 2007; 21: 136-142.
5. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59-66.
6. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154-1163.
7. May AE, Neumann FJ, Schomig A, Preissner KT. VLA-4 (alpha(4)beta(1)) engagement defines a novel activation pathway for beta(2) integrin-dependent leukocyte adhesion involving the urokinase receptor. Blood 2000; 96: 506-513.
8. Bohnsack JF, Chang J. Activation of beta 1 integrin fibronectin receptors on HL60 cells after granulocytic differentiation. Blood 1994; 83: 543-552.
9. Pilat MJ, Lorusso PM. Vascular disrupting agents. J Cell Biochem 2006; 99: 1021-1039.
10. Zhao D, Richer E, Antich PP, Mason RP. Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI. FASEB J 2008; 22: 2445-2451.
11. Chaplin DJ, Hill SA. The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys 2002; 54: 1491-1496.
12. Salmon HW, Mladinich C, Siemann DW. Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique. Eur J Cancer 2006; 42: 3073-3078.
13. Holwell SE, Cooper PA, Grosios K, Lippert III JW, Pettit GR, Shnyder SD et al. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours. Anticancer Res 2002; 22: 707-711.
14. Wankhede M, Dedeugd C, Siemann DW, Sorg BS. In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503. Oncol Rep 2010; 23: 685-692.
15. Chan LS, Malcontenti-Wilson C, Muralidharan V, Christophi C. Effect of vascular targeting agent Oxi4503 on tumor cell kinetics in a mouse model of colorectal liver metastasis. Anticancer Res 2007; 27: 2317-2323.
16. Chan LS, Malcontenti-Wilson C, Muralidharan V, Christophi C. Alterations in vascular architecture and permeability following OXi4503 treatment. Anticancer Drugs 2008; 19: 17-22.
17. Daenen LG, Shaked Y, Man S, Xu P, Voest EE, Hoffman RM et al. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther 2009; 8: 2872-2881.
18. Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 2008; 28: 2027-2031.
19. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM et al. Therapyinduced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006; 313: 1785-1787.
20. Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, Scott EW et al. Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 2010; 116: 1539-1547.
21. Hill SA, Toze GM, Pettit GR, Chaplin DJ. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res 2002; 22: 1453-1458.
22. Holwell SE, Cooper PA, Thompson MJ, Pettit GR, Lippert III LW, Martin SW et al. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. Anticancer Res 2002; 22: 3933-3940.
23. Salmon HW, Siemann DW. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res 2006; 12: 4090-4094.
24. Madlambayan GJ, Meacham A, Hosaka K, Mir S, Jorgensen M, Scott EW et al. Leukemia regression by vascular disruption and anti-angiogenic therapy. Blood 2010; 116: 1539-1547.
25. Hua J, Sheng Y, Pinney KG, Garner CM, Kane RR, Prezioso JA et al. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res 2003; 23: 1433-1440.
26. Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR et al. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 1988; 34: 200-208.
27. Seshadri M, Toth K. Acute vascular disruption by 5,6-dimethylxanthenone- 4-acetic acid in an orthotopic model of human head and neck cancer. Transl Oncol 2009; 2: 121-127.
28. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003; 21: 2823-2830.
29. Contag CH, Jenkins D, Contag PR, Negrin RS. Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia 2000; 2: 41-52.
30. Edinger M, Cao YA, Hornig YS, Jenkins DE, Verneris MR, Bachmann MH et al. Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer 2002; 38: 2128-2136.
31. Bradbury MS, Panagiotakos G, Chan BK, Tomishima M, Zanzonico P, Vider J et al. Optical bioluminescence imaging of human ES cell progeny in the rodent CNS. J Neurochem 2007; 102: 2029-2039.
32. Agliano A, Martin-Padura I, Mancuso P, Marighetti P, Rabascio C, Pruneri G et al. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 2008; 123: 2222-2227.
33. Pettit GR, Thornhill AJ, Moser BR, Hogan F. Antineoplastic agents. 552. Oxidation of combretastatin A-1: trapping the o-quinone intermediate considered the metabolic product of the corresponding phosphate prodrug. J Nat Prod 2008; 71: 1561-1563.
34. Folkes LK, Christlieb M, Madej E, Stratford MR, Wardman P. Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals. Chem Res Toxicol 2007; 20: 1885-1894.
35. Kirwan IG, Loadman PM, Swaine DJ, Anthoney DA, Pettit GR, Lippert III JW et al. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin Cancer Res 2004; 10: 1446-1453.
36. Inoue Y, Izawa K, Kiryu S, Kobayashi S, Tojo A, Ohtomo K. Bioluminescent evaluation of the therapeutic effects of total body irradiation in a murine hematological malignancy model. Exp Hematol 2008; 36: 1634-1641.
37. Jurczok A, Fornara P, Soling A. Bioluminescence imaging to monitor bladder cancer cell adhesion in vivo: a new approach to optimize a syngeneic, orthotopic, murine bladder cancer model. BJU Int 2008; 101: 120-124.
38. Malcontenti-Wilson C, Chan L, Nikfarjam M, Muralidharan V, Christophi C. Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model. J Gastroenterol Hepatol 2008; 23 (7 Part 2): e96-e104.